Chunkit Fung1, Sophie D Fossa1, Michael T Milano1, Deepak M Sahasrabudhe1, Derick R Peterson1, Lois B Travis2. 1. Chunkit Fung, Michael T. Milano, Deepak M. Sahasrabudhe, Derick R. Peterson, and Lois B. Travis, University of Rochester Medical Center, Rochester, NY; and Sophie D. Fossa, Norwegian Radium Hospital, Oslo, Norway. 2. Chunkit Fung, Michael T. Milano, Deepak M. Sahasrabudhe, Derick R. Peterson, and Lois B. Travis, University of Rochester Medical Center, Rochester, NY; and Sophie D. Fossa, Norwegian Radium Hospital, Oslo, Norway. malmile@iu.edu.
Abstract
PURPOSE: Increased risks of incident cardiovascular disease (CVD) in patients with testicular cancer (TC) given chemotherapy in European studies were largely restricted to long-term survivors and included patients from the 1960s. Few population-based investigations have quantified CVD mortality during, shortly after, and for two decades after TC diagnosis in the era of cisplatin-based chemotherapy. PATIENTS AND METHODS: Standardized mortality ratios (SMRs) for CVD and absolute excess risks (AERs; number of excess deaths per 10,000 person-years) were calculated for 15,006 patients with testicular nonseminoma reported to the population-based Surveillance, Epidemiology, and End Results program (1980 to 2010) who initially received chemotherapy (n=6,909) or surgery (n=8,097) without radiotherapy and accrued 60,065 and 81,227 person-years of follow-up, respectively. Multivariable modeling evaluated effects of age, treatment, extent of disease, and other factors on CVD mortality. RESULTS: Significantly increased CVD mortality occurred after chemotherapy (SMR, 1.36; 95% CI, 1.03 to 1.78; n=54) but not surgery (SMR, 0.81; 95% CI, 0.60 to 1.07; n=50). Significant excess deaths after chemotherapy were restricted to the first year after TC diagnosis (SMR, 5.31; AER, 13.90; n=11) and included cerebrovascular disease (SMR, 21.72; AER, 7.43; n=5) and heart disease (SMR, 3.45; AER, 6.64; n=6). In multivariable analyses, increased CVD mortality after chemotherapy was confined to the first year after TC diagnosis (hazard ratio, 4.86; 95% CI, 1.25 to 32.08); distant disease (P<.05) and older age at diagnosis (P<.01) were independent risk factors. CONCLUSION: This is the first population-based study, to our knowledge, to quantify short- and long-term CVD mortality after TC diagnosis. The increased short-term risk of CVD deaths should be further explored in analytic studies that enumerate incident events and can serve to develop comprehensive evidence-based approaches for risk stratification and application of preventive and interventional efforts.
PURPOSE: Increased risks of incident cardiovascular disease (CVD) in patients with testicular cancer (TC) given chemotherapy in European studies were largely restricted to long-term survivors and included patients from the 1960s. Few population-based investigations have quantified CVD mortality during, shortly after, and for two decades after TC diagnosis in the era of cisplatin-based chemotherapy. PATIENTS AND METHODS: Standardized mortality ratios (SMRs) for CVD and absolute excess risks (AERs; number of excess deaths per 10,000 person-years) were calculated for 15,006 patients with testicular nonseminoma reported to the population-based Surveillance, Epidemiology, and End Results program (1980 to 2010) who initially received chemotherapy (n=6,909) or surgery (n=8,097) without radiotherapy and accrued 60,065 and 81,227 person-years of follow-up, respectively. Multivariable modeling evaluated effects of age, treatment, extent of disease, and other factors on CVD mortality. RESULTS: Significantly increased CVD mortality occurred after chemotherapy (SMR, 1.36; 95% CI, 1.03 to 1.78; n=54) but not surgery (SMR, 0.81; 95% CI, 0.60 to 1.07; n=50). Significant excess deaths after chemotherapy were restricted to the first year after TC diagnosis (SMR, 5.31; AER, 13.90; n=11) and included cerebrovascular disease (SMR, 21.72; AER, 7.43; n=5) and heart disease (SMR, 3.45; AER, 6.64; n=6). In multivariable analyses, increased CVD mortality after chemotherapy was confined to the first year after TC diagnosis (hazard ratio, 4.86; 95% CI, 1.25 to 32.08); distant disease (P<.05) and older age at diagnosis (P<.01) were independent risk factors. CONCLUSION: This is the first population-based study, to our knowledge, to quantify short- and long-term CVD mortality after TC diagnosis. The increased short-term risk of CVD deaths should be further explored in analytic studies that enumerate incident events and can serve to develop comprehensive evidence-based approaches for risk stratification and application of preventive and interventional efforts.
Authors: Hege S Haugnes; Torgeir Wethal; Nina Aass; Olav Dahl; Olbjørn Klepp; Carl W Langberg; Tom Wilsgaard; Roy M Bremnes; Sophie D Fosså Journal: J Clin Oncol Date: 2010-09-20 Impact factor: 44.544
Authors: Lois B Travis; Clair Beard; James M Allan; Alv A Dahl; Darren R Feldman; Jan Oldenburg; Gedske Daugaard; Jennifer L Kelly; M Eileen Dolan; Robyn Hannigan; Louis S Constine; Kevin C Oeffinger; Paul Okunieff; Greg Armstrong; David Wiljer; Robert C Miller; Jourik A Gietema; Flora E van Leeuwen; Jacqueline P Williams; Craig R Nichols; Lawrence H Einhorn; Sophie D Fossa Journal: J Natl Cancer Inst Date: 2010-06-28 Impact factor: 13.506
Authors: Sophie D Fosså; Milada Cvancarova; Linlin Chen; Annie L Allan; Jan Oldenburg; Derick R Peterson; Lois B Travis Journal: J Clin Oncol Date: 2011-02-07 Impact factor: 44.544
Authors: Alexandra W van den Belt-Dusebout; Ronald de Wit; Jourik A Gietema; Simon Horenblas; Marieke W J Louwman; Jacques G Ribot; Harald J Hoekstra; Gabey M Ouwens; Berthe M P Aleman; Flora E van Leeuwen Journal: J Clin Oncol Date: 2007-10-01 Impact factor: 44.544
Authors: Saamir A Hassan; Nicolas Palaskas; Peter Kim; Cezar Iliescu; Juan Lopez-Mattei; Elie Mouhayar; Rohit Mougdil; Kara Thompson; Jose Banchs; Syed Wamique Yusuf Journal: Curr Atheroscler Rep Date: 2018-02-08 Impact factor: 5.113
Authors: Mohammad Abu Zaid; Wambui G Gathirua-Mwangi; Chunkit Fung; Patrick O Monahan; Omar El-Charif; Annalynn M Williams; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Ryan Cook; Sandra K Althouse; Shirin Ardeshir-Rouhani-Fard; Paul C Dinh; Howard D Sesso; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis Journal: J Natl Compr Canc Netw Date: 2018-03 Impact factor: 11.908
Authors: Stanley A Yap; Lindsay M Yuh; Christopher P Evans; Marc A Dall'Era; Rebecca M Wagenaar; Rosemary Cress; Primo N Lara Journal: World J Urol Date: 2016-06-15 Impact factor: 4.226
Authors: Mohammad Abu Zaid; Paul C Dinh; Patrick O Monahan; Chunkit Fung; Omar El-Charif; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Ryan Cook; Sandra Althouse; Shirin Ardeshir-Rouhani-Fard; Howard D Sesso; Robert Huddart; Taisei Mushiroda; Michiaki Kubo; M Eileen Dolan; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis Journal: J Natl Compr Canc Netw Date: 2019-05-01 Impact factor: 11.908